Annalee Armstrong is a Senior Editor at Fierce Pharma. She specializes in medicine and healthcare, with a focus on pharmaceuticals, pharmaceutical manufacturing, and regulation, as well as global markets. Annalee's work has been featured in outlets such as RamaOnHealthcare, Biotech, NewsBreak, BioSpace, and the Kimberley Bulletin.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Annalee Armstrong's coverage heavily focuses on the healthcare and pharmaceutical industry, particularly in biotech, drug discovery, fundraising, pharmaceutical companies, and clinical trials. Her articles often cite data or press releases.
If you're looking to reach out to Annalee with a pitch, consider offering access to exclusive data or insights related to developments within the biotech and pharmaceutical sectors. This could include information about new clinical trials, fundraising efforts by healthcare companies or breakthroughs in drug discovery.
It's important for sources reaching out to Annalee Armstrong to provide fact-based evidence that supports their pitches as it aligns with her focus on citing data in her articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Annalee Armstrong
Eli Lilly sauntered into the American Diabetes Association meeting with a commanding lead in the metabolic space and put down more evidence for its pipeline, including new pill Foundayo and next-gen asset retatrutide, in new indications.
By: Annalee Armstrong
Incyte is acquiring Vega Therapeutics, a subsidiary of Star Therapeutics, for a bleeding disorder program that analysts say has “pipeline-in-a-product” potential.
By: Annalee Armstrong
After a $625 million IPO, the biggest ever in biotech, obesity-focused Kailera Therapeutics is readying a commercial strategy that puts patients at the center.
Over the past decade, Eli Lilly has bought out more biotechs than any of the other top 12 pharmas by revenue—with 10 of those acquisitions arriving just this year.
By: Annalee Armstrong
Members of the American Biotech Innovation Alliance (ABIA) want to build a national biotech strategy—just like China did years ago.
By: Jef Akst, Annalee Armstrong, Heather Mckenzie, Gabrielle Masson
Eli Lilly and obesity rival Novo Nordisk stole the show at the American Diabetes Association conference, though plenty of other companies also had data to show for their own weight loss assets; GSK strikes the biggest traditional pharma buyout of 2026; and FDA initiatives still lack clarity.
By: Annalee Armstrong
Biotechs are benefitting from the AI tech frenzy and inflation, but validated pipelines and careful planning are still key to the recent record-setting IPOs, experts say.
The Vaccines and Related Biological Products Advisory Committee will meet June 18 to discuss Moderna's seasonal flu vaccine mRNA-1010 after the FDA initially refused to accept the application in February.
By: Heather Mckenzie, Annalee Armstrong, Gabrielle Masson, Jef Akst
Moderna appears to have aligned with the FDA ahead of an advisory committee meeting for its mRNA-based flu vaccine, which the regulator initially turned away in February; biotech IPOs are going gangbusters, including two new records raises in as many weeks; layoffs continue across biopharma; plus…
By: Annalee Armstrong
Denali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year.
